**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) A method of treating hot flashes in a patient comprising administering to the patient in need of such treatment a therapeutically effective amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof.

2. (Previously presented) A method of treating hot flashes in a patient comprising administering to the patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle.

3. (Cancelled)

4 . (Previously presented) The method of Claim 1 or Claim 2, wherein the patient is an adult and the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof is administered in a dose of 300 to 3600 mg gabapentin equivalents per day.

5. (Previously presented) The method of Claim 1 or Claim 2, wherein the patient is a female patient.

6. (Original) The method of Claim 5, wherein the female patient is postmenopausal.

7. (Original) The method of Claim 6, wherein menopause is drug induced or surgically induced.

8. (Previously presented) The method of Claim 1 or Claim 2, wherein the patient is a male patient.

9. (Previously presented) The method of Claim 5, wherein the hot flashes are drug-induced.

10. (Cancelled)

11. (Previously presented) The method of Claim 1 or Claim 2, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof is administered orally.

12. (Previously presented) The method of Claim 2, wherein the pharmaceutical composition is a sustained release oral dosage form.

13. (Previously presented) The method of Claim 12, wherein the dosage form releases the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid gradually over a period of at least about 6 hours after swallowing the dosage form, thereby providing a therapeutic concentration of 1-(aminomethyl)cyclohexane acetic acid in the plasma of the patient.

14-27. (Cancelled)

28. (Previously presented) The method of Claim 5, wherein the female patient is menopausal.

29-36. (Cancelled)

37. (Previously presented) The method of Claim 8, wherein the hot flashes are drug-induced.

38-40. (Cancelled)

41. (Previously presented) The method of claim 1 or claim 2, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof is 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.

42. (Previously presented) The method of claim 13, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof is 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.